Sindhu Johnson, MD, PhD, FRCPC, has co-chaired the classification and response criteria subcommittee and brings extensive experience in classification and guideline development to her new role.
ACR Leverages AMA Representation to Advance Rheumatology Issues
The ACR’s delegation to the AMA HOD meeting in November successfully advanced resolutions to advocate for pharmacy benefit manager transparency and expanded patient protections from step therapy protocols.
Progress on Preventing Immune-Related Adverse Events
ATLANTA—One of the hottest topics in medicine is the emerging field of cancer immunotherapy. However, immune-related adverse events (irAEs) are associated with the therapy, and when things go wrong, they can go very, very wrong, said Ryan Sullivan, MD, during the 2019 ACR/ARP Annual Meeting in November. “The guiding principle of cancer immunotherapy is [that]…
Collegiality—an ARP Mainstay
ATLANTA—In the late 1990s, at the Annual Meeting, a colleague asked Marian Hannan, DSc, MSc, who is now professor of medicine at Harvard Medical School, if she wanted to go to a tourist attraction and talk about professional pursuits during a break at the conference. The colleague ranked higher than she did, and she didn’t…
A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis
ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…
New Draft Gout Guideline Released
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…
Year in Review: Rheumatic Disease Research in 2019
ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…
FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin
The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…
Atmospheric & Environmental Changes Tied to Organ-Specific Lupus Flares
NEW YORK (Reuters Health)—Changes in atmospheric and environmental factors may contribute to organ-specific disease exacerbation in patients with systemic lupus erythematosus (SLE), according to a new study. The study found “strong associations between atmospheric variables and fine particulate matter concentration over the 10 days prior to a patient visit and organ-specific lupus flares at the…
Antibiotic Use Linked to Higher Risk for RA
New research finds patients previously treated with antibiotics, antifungals and antivirals may be more likely to develop rheumatoid arthritis than patients who have not received these treatments…
- « Previous Page
- 1
- …
- 229
- 230
- 231
- 232
- 233
- …
- 814
- Next Page »